Similar articles

• Intermittent, short term use of methotrexate for exacerbations of psoriasis.

  Clark AR, Feldman SR. Clark AR, et al. Int J Dermatol. 1997 Dec;36(12):954-5. doi: 10.1046/j.1365-4362.1997.d01-663.x. Int J Dermatol. 1997. PMID: 9466209 No abstract available.
• Methotrexate and psoriasis in the era of new biologic agents.

  Saporito FC, Menter MA. Saporito FC, et al. J Am Acad Dermatol. 2004 Feb;50(2):301-9. doi: 10.1016/s0190-9622(03)00803-x. J Am Acad Dermatol. 2004. PMID: 14726893 Review. No abstract available.
• Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis.

  Affleck A, Goudie A, Smith R. Affleck A, et al. Clin Exp Dermatol. 2019 Jul;44(5):591-592. doi: 10.1111/ced.13972. Epub 2019 Apr 26. Clin Exp Dermatol. 2019. PMID: 30919996 No abstract available.
• Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.

  Kalb RE, Strober B, Weinstein G, Lebwohl M. Kalb RE, et al. J Am Acad Dermatol. 2009 May;60(5):824-37. doi: 10.1016/j.jaad.2008.11.906. J Am Acad Dermatol. 2009. PMID: 19389524
• Yellow nail pigmentation due to methotrexate.

  Malka N, Reichert S, Trechot P, Barbaud A, Schmutz JL. Malka N, et al. Dermatology. 1998;197(3):276. Dermatology. 1998. PMID: 9867364 No abstract available.